For decades, metformin has been one of the most familiar medicines in diabetes care. It is inexpensive, widely prescribed and generally well understood.
So when doctors observed significant tumor shrinkage in a young patient with advanced adrenal cancer after metformin was added to treatment, the finding naturally attracted attention.
Could an old diabetes medicine have a new role in cancer treatment?
Possibly—but it is far too early to say.
The case is interesting because cancer cells have unusual ways of producing and using energy. Researchers are increasingly studying these metabolic differences in an effort to find new ways to make tumors more vulnerable to treatment.
At the same time, oncologists emphasize an important distinction: an encouraging response in one patient is not evidence that metformin treats cancer generally.
Why Metformin Is Interesting to Cancer Researchers
Metformin primarily works by reducing glucose production by the liver and improving insulin sensitivity.
Cancer biology is much more complicated than simply having too much glucose, but metabolism does play an important role in tumor growth.
Many cancer cells dramatically alter the way they obtain and use energy. This metabolic flexibility helps tumors survive under difficult conditions and continue producing the materials required for rapid cell division.
This has led researchers to ask an intriguing question: Could medicines that influence cellular metabolism also affect cancer cells?
Metformin is one of the drugs being investigated.
Laboratory research suggests that the medication can influence mitochondrial energy production and cellular signaling pathways involved in growth. It may also alter insulin-related signaling in the body.
But laboratory findings are only the beginning of the process.
The Warburg Effect: Cancer’s Unusual Energy Strategy
One of the best-known observations in cancer metabolism is called the Warburg effect.
Normal cells can produce energy through mitochondrial respiration, while many cancer cells rely heavily on glycolysis even when oxygen is available.
This doesn’t mean every cancer behaves identically. Tumors are remarkably diverse, and different cancers—and even different cells within the same tumor—can use different metabolic strategies.
That complexity is one reason a treatment that looks promising in laboratory experiments may produce very different results in patients.
Cancer cells can adapt.
They may switch fuel sources, change signaling pathways or rely on alternative metabolic routes when one pathway is blocked.
Researchers therefore aren’t simply trying to “starve” cancer cells. They are investigating whether metabolic weaknesses can be combined with existing treatments to make cancer harder for tumors to survive.
What Metformin May Be Doing Inside Cells
Several biological mechanisms have been proposed to explain why metformin might influence tumor behavior.
One involves mitochondria, the structures responsible for much of a cell’s energy production. Metformin can affect mitochondrial respiration, particularly through its interaction with complex I.
This can alter the cell’s energy balance and activate AMP-activated protein kinase, or AMPK, an important cellular energy sensor.
AMPK helps cells respond when energy availability changes. Its activation can influence pathways involved in growth and protein production, including the mTOR pathway.
Metformin may also influence cancer indirectly by improving insulin sensitivity and reducing circulating insulin in some people.
These mechanisms are biologically interesting, but a plausible mechanism does not automatically translate into a successful cancer treatment.
That distinction is crucial.
Why One Patient’s Tumor Response Isn’t Enough
A case report can be extremely valuable.
Sometimes an unusual response alerts researchers to a previously overlooked biological pathway and eventually leads to a clinical trial.
But a single patient’s outcome cannot establish whether a medicine caused the response.
Cancer patients may receive several treatments simultaneously or sequentially. Tumors can also behave unpredictably, and their genetic characteristics can influence how they respond.
To determine whether metformin genuinely improves cancer outcomes, researchers need controlled clinical studies involving substantially larger groups of patients.
These studies can answer questions that a case report cannot:
- Does metformin improve tumor response rates?
- Does it extend progression-free or overall survival?
- Which patients, if any, benefit?
- What dose is appropriate?
- Does it work better alongside chemotherapy, radiation or immunotherapy?
- What risks emerge with longer-term use?
Until those questions are answered, metformin remains an area of investigation rather than an established cancer therapy.
The Bigger Idea: Metabolic Oncology
The excitement surrounding metformin reflects a broader change in cancer research.
Scientists are increasingly interested in metabolic oncology, which examines how tumors obtain energy, build new cells and adapt to changing conditions.
The goal isn’t necessarily to replace established cancer treatments.
Instead, researchers are exploring whether metabolic interventions could complement chemotherapy, radiation, targeted medicines or immunotherapy.
This approach could eventually help doctors identify tumors with particular metabolic weaknesses and match treatments more precisely to individual patients.
That is part of the larger movement toward personalized cancer medicine.
What Patients Should Take From the Research
The most important message is not that people should start taking metformin to prevent or treat cancer.
People who have diabetes or another medical reason to take metformin should continue discussing its use with their healthcare professional. Those who do not have an indication for the medication should not self-medicate based on preliminary cancer research.
Metformin can cause side effects and is not appropriate for everyone. Medication decisions become particularly important for people with kidney problems or other medical conditions.
For cancer patients, the safest approach is to discuss emerging treatments with their oncology team rather than replacing proven therapy with an experimental approach.
A Promising Clue, Not a Cancer Cure
The story of a diabetes medication being associated with an unexpected tumor response is exactly the kind of observation that can push medical research in a new direction.
But good science requires patience.
A remarkable case can generate a hypothesis. Laboratory experiments can provide a possible explanation. Clinical trials must then determine whether that explanation actually benefits patients.
Metformin may ultimately prove useful for particular cancers or patient groups—or researchers may discover that its apparent benefits are more limited than early findings suggest.
For now, the most responsible conclusion is also the most encouraging: scientists have found another potential clue in the complicated relationship between metabolism and cancer.
The next step isn’t hype. It is better research.
Photo by Tima Miroshnichenko: https://www.pexels.com/photo/bald-woman-wearing-a-hospital-gown-6010809/